2024–2025 Clinical & Translational Update — KRAS G12C Inhibitors, MSI-H Immunotherapy, BRAF V600E Combinations, HER2-Targeted Therapy, Anti-EGFR Rechallenge & ctDNA MRD-Guided Strategies
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States, with metastatic CRC (mCRC) carrying a five-year survival rate of approximately 14%. The treatment landscape has undergone a rapid and fundamental shift — from cytotoxic backbone chemotherapy to molecularly targeted, biomarker-driven precision strategies. The identification of actionable molecular subtypes — KRAS/NRAS/BRAF mutations, HER2 amplification, MSI-H/dMMR status, and KRAS G12C — has fragmented what was once a largely uniform disease into distinct therapeutic niches, each with dedicated targeted agents. Simultaneously, circulating tumor DNA (ctDNA) as a minimal residual disease (MRD) tool is poised to transform adjuvant decision-making across all CRC stages.
Pembrolizumab · Nivolumab · Nivolumab + Ipilimumab
Encorafenib + Cetuximab · + Binimetinib (triplet)
Cetuximab · Panitumumab · Rechallenge strategies
Sotorasib · Adagrasib · Divarasib · Glecirasib
Trastuzumab Deruxtecan · Tucatinib + Trastuzumab · Pertuzumab
Signatera · FoundationOne Tracker · Guardant Infinity
First Phase 3 trial to demonstrate superiority of a KRAS G12C inhibitor combination in mCRC. Sotorasib 960mg + panitumumab vs standard of care (TAS-102 or regorafenib) in previously treated KRAS G12C-mutant mCRC. FDA approved August 2024 — the first approved KRAS G12C-targeted regimen in CRC. Confirmed the necessity of dual EGFR/KRAS blockade over KRAS inhibition alone.
Five-year landmark update at ASCO 2024 confirms durable PFS and OS benefit of pembrolizumab over FOLFOX/FOLFIRI ± bevacizumab/cetuximab in MSI-H/dMMR mCRC. Approximately 20% of pembrolizumab-treated patients remain progression-free at 5 years vs near-zero in the chemotherapy arm. Long-term responder characteristics: right-sided, high TMB, POLE/POLD1-mutant subgroups enriched for exceptional response.
Investigational frontline use of encorafenib + cetuximab with or without mFOLFOX6 in previously untreated BRAF V600E mCRC. Safety run-in completed; triplet arm (encorafenib + cetuximab + FOLFOX) granted FDA Breakthrough Therapy Designation based on early response data showing ORR >60%. This trial has potential to displace FOLFOXIRI + bevacizumab as frontline standard in BRAF V600E disease if primary endpoints are met.
T-DXd at 5.4mg/kg demonstrated ORR 37.8% in HER2-overexpressing/amplified mCRC across multiple prior lines. Confirmed superiority of lower dose (5.4mg/kg) vs higher dose (6.4mg/kg) in terms of safety/efficacy balance. Interstitial lung disease (ILD) monitoring essential. FDA Breakthrough Therapy Designation granted. DESTINY-CRC03 (randomized) comparing T-DXd vs standard of care is now enrolling.
DYNAMIC (Stage II): ctDNA-guided adjuvant therapy decision-making was non-inferior for 3-year recurrence-free survival while reducing chemotherapy use by 50% vs standard clinicopathologic risk-based selection. DYNAMIC-III (Stage III) now enrolling to validate ctDNA-based FOLFOX escalation or de-escalation. These trials represent the vanguard of ctDNA MRD integration into curative-intent CRC management.
Short-course neoadjuvant dual checkpoint blockade (nivolumab + ipilimumab × 2 cycles) prior to surgery in localized dMMR colon cancer. Pathologic complete response (pCR) rate 67% — a landmark result redefining the role of surgery in dMMR CRC. Near-complete responses: 95%. Organ-preservation strategies (watch-and-wait) now under active investigation in dMMR rectal cancer following total neoadjuvant therapy.
~95% of mCRC is microsatellite stable (MSS) — profoundly resistant to single-agent PD-1/PD-L1 checkpoint blockade. Strategies to convert MSS tumors to immunotherapy-sensitive states are an urgent priority: MEK inhibitors, TGF-beta blockade, oncolytic viruses, and CAR-T cells are under active investigation. No approved immunotherapy strategy exists for MSS mCRC as of 2025.
Despite compelling Phase 3 data, acquired resistance to KRAS G12C inhibitors develops rapidly — via KRAS amplification, secondary KRAS mutations, RAS/MAPK pathway reactivation, and EGFR bypass signaling. Next-generation pan-KRAS and KRAS G12C/D inhibitors (BI 1701963, RMC-6236) are in early trials. Combination strategies targeting multiple resistance nodes simultaneously are a key 2025 priority.
Anti-EGFR rechallenge is active in approximately 30% of previously responding patients — but identifying eligible patients requires ctDNA clearance of acquired RAS/BRAF mutations. The CHRONOS and CRICKET trials demonstrate proof of concept; however standardizing liquid biopsy-guided rechallenge in clinical practice requires regulatory-grade ctDNA assay validation and prospective data.
Multiple ctDNA MRD platforms (Signatera, Guardant Infinity, FoundationOne Tracker) demonstrate clinical validity but lack head-to-head comparisons. Analytical and clinical concordance across platforms is not established. Reimbursement, turnaround time, and reporting standards vary significantly. FDA clearance pathways for MRD-guided treatment decisions remain in development for CRC.
Colorectal cancer incidence in adults under 50 has increased ~2% annually since the mid-1990s. Early-onset CRC (EOCRC) has distinct molecular features — enriched for MSI-H, POLE/POLD1 mutations, and proficient MMR with hypermutated signatures — compared to older-onset disease. Screening guidelines are being updated; optimal molecular characterization of EOCRC to guide therapy represents an emerging research frontier.
Total neoadjuvant therapy (TNT) followed by watch-and-wait (W&W) in clinical complete responders is reshaping rectal cancer management. OPRA trial: organ preservation achieved in ~43% at 3 years with TNT. dMMR rectal cancer with neoadjuvant immunotherapy achieving pCR may avoid surgery entirely. Standardization of W&W protocols and long-term recurrence monitoring remain active areas of investigation.
Stage II / III — resected CRC: Adjuvant FOLFOX (Stage III; high-risk Stage II). Mandatory ctDNA MRD testing post-resection — ctDNA-positive patients should receive adjuvant chemotherapy; ctDNA-negative low-risk Stage II patients may be spared (DYNAMIC data). MSI-H Stage II: adjuvant chemotherapy benefit unclear — likely none; watch-and-wait or trial enrollment preferred. dMMR rectal cancer: neoadjuvant immunotherapy (NICHE-2 protocol) achieves pCR in ~67%.
MSI-H/dMMR: Pembrolizumab monotherapy (KEYNOTE-177). BRAF V600E: Encorafenib + cetuximab; consider BREAKWATER triplet if enrollable. RAS/BRAF WT, left-sided: Anti-EGFR (panitumumab or cetuximab) + FOLFOX or FOLFIRI — PARADIGM confirms panitumumab + mFOLFOX6 as preferred. RAS mutant or right-sided: FOLFOX/FOLFIRI + bevacizumab. HER2+: MOUNTAINEER-03 (trial preferred) or tucatinib + trastuzumab + FOLFOX.
Post-oxaliplatin: FOLFIRI ± bevacizumab or anti-EGFR (if RAS WT, left-sided, EGFR-naive). Post-irinotecan: FOLFOX ± targeted agent. HER2+ (post-chemo): Tucatinib + trastuzumab (MOUNTAINEER) or T-DXd (DESTINY-CRC02). KRAS G12C (post-1st line): Sotorasib + panitumumab (FDA approved) or adagrasib + cetuximab (imminent approval). Anti-EGFR rechallenge if ctDNA clears acquired RAS mutations (CHRONOS protocol).
MSI-H progression post-pembrolizumab: FOLFOX/FOLFIRI; consider ipilimumab + nivolumab (CheckMate 142). NTRK fusion (rare, ~0.5%): Larotrectinib or entrectinib (tissue-agnostic FDA approvals). RET fusion (~0.2%): Selpercatinib. POLE/POLD1 ultramutated: Exceptional immunotherapy responders — pembrolizumab preferred regardless of MSI status. CDX2-low: Potential biomarker for adjuvant chemotherapy benefit in Stage II — emerging evidence.
Post-fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF, anti-EGFR: Regorafenib (CORRECT) or TAS-102/trifluridine-tipiracil ± bevacizumab (SUNLIGHT: OS HR 0.61). Clinical trial enrollment is strongly preferred over regorafenib monotherapy in eligible patients. Investigational options: anti-CEA bispecific antibodies (RG6123), WRN inhibitor (HRR-deficient MSS CRC), SHP2/KRASG12X inhibitor combinations, and cancer vaccines in MSI-H.
Colorectal cancer is rapidly fragmenting into molecularly defined subtypes, each with dedicated therapeutic strategies. The FDA approval of sotorasib + panitumumab for KRAS G12C mCRC in August 2024 represents the culmination of decades of effort to drug the "undruggable" KRAS mutation — and signals that the remaining KRAS variants (G12D, G12V) are now firmly in the crosshairs of next-generation inhibitor programs.
The most transformative near-term shift is the integration of ctDNA MRD into adjuvant decision-making. DYNAMIC demonstrates that half of Stage II CRC patients can be spared chemotherapy without compromising outcomes — a practice-changing finding that challenges the current clinicopathologic risk-based approach and will reshape oncology workflows as FDA clearance pathways mature.
The fundamental unmet need remains MSS/pMMR mCRC — comprising 95% of metastatic disease and resistant to available immunotherapies. Rational combinations targeting the immunosuppressive tumor microenvironment, including TGF-beta/PD-L1 bispecifics (bintrafusp alfa), anti-CEA CAR-T cells, and synthetic lethality strategies exploiting WRN helicase dependence in MSI-like MSS tumors, represent the next scientific frontier.
Key trials to watch: BREAKWATER OS data, DYNAMIC-III primary endpoint, KRYSTAL-10 FDA review, MOUNTAINEER-03 survival data, DESTINY-CRC03, OPRA 5-year organ preservation rates, and WRN inhibitor Phase 1/2 data at ASCO 2025 and ESMO 2025.